{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:46:57Z","timestamp":1791935217821,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-05407-w","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:15:05Z","timestamp":1790561705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stage-dependent alterations in MaR1 in pediatric chronic kidney disease: a potential candidate biomarker"],"prefix":"10.1186","volume":"27","author":[{"given":"Muhammet Akif","family":"Guler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Halici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"Bayraktutan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir Enis","family":"Yurdgulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Anil","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4491-1327","authenticated-orcid":false,"given":"Halil","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"5407_CR1","doi-asserted-by":"publisher","unstructured":"Wise PH. The future pediatrician: the challenge of chronic illness. J Pediatr. 2007;151(5). https:\/\/doi.org\/10.1016\/j.jpeds.2007.08.013.","DOI":"10.1016\/j.jpeds.2007.08.013"},{"key":"5407_CR2","doi-asserted-by":"publisher","unstructured":"Jain S, Dewey RS. The role of special clinics in imparting clinical skills: medical education for competence and sophistication. Adv Med Educ Pract. 2021;12. https:\/\/doi.org\/10.2147\/AMEP.S306214.","DOI":"10.2147\/AMEP.S306214"},{"key":"5407_CR3","doi-asserted-by":"publisher","unstructured":"Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al. Global, regional, and national causes of under-5 mortality in 2000\u201319: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet Child Adolesc Health. 2022;6(2). https:\/\/doi.org\/10.1016\/S2352-4642(21)00311-4.","DOI":"10.1016\/S2352-4642(21)00311-4"},{"issue":"6","key":"5407_CR4","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/S00467-021-05145-1","volume":"37","author":"R Harada","year":"2022","unstructured":"Harada R, Hamasaki Y, Okuda Y, Hamada R, Ishikura K. Epidemiology of pediatric chronic kidney disease\/kidney failure: learning from registries and cohort studies. Pediatr Nephrol. 2022;37(6):1215\u201329. https:\/\/doi.org\/10.1007\/S00467-021-05145-1.","journal-title":"Pediatr Nephrol"},{"key":"5407_CR5","doi-asserted-by":"publisher","unstructured":"Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, et al. KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020;104(4). https:\/\/doi.org\/10.1097\/TP.0000000000003136.","DOI":"10.1097\/TP.0000000000003136"},{"key":"5407_CR6","doi-asserted-by":"publisher","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4). https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"5407_CR7","doi-asserted-by":"publisher","DOI":"10.1159\/000368940","author":"OM Akchurin","year":"2015","unstructured":"Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015. https:\/\/doi.org\/10.1159\/000368940.","journal-title":"Blood Purif"},{"key":"5407_CR8","doi-asserted-by":"publisher","unstructured":"Lai HL, Kartal J, Mitsnefes M. Hyperinsulinemia in pediatric patients with chronic kidney disease: the role of tumor necrosis factor-\u03b1. Pediatr Nephrol. 2007;22(10). https:\/\/doi.org\/10.1007\/s00467-007-0533-z.","DOI":"10.1007\/s00467-007-0533-z"},{"issue":"10","key":"5407_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/S11906-024-01308-1","volume":"26","author":"NG Larkins","year":"2024","unstructured":"Larkins NG, Craig JC. Hypertension and cardiovascular risk among children with chronic kidney disease. Curr Hypertens Rep. 2024;26(10):389\u201398. https:\/\/doi.org\/10.1007\/S11906-024-01308-1.","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"5407_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41581-024-00889-z","volume":"21","author":"V Miguel","year":"2025","unstructured":"Miguel V, Shaw IW, Kramann R. Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease. Nat Rev Nephrol. 2025;21(1):39\u201356. https:\/\/doi.org\/10.1038\/s41581-024-00889-z.","journal-title":"Nat Rev Nephrol"},{"key":"5407_CR11","doi-asserted-by":"publisher","unstructured":"Stenvinkel P, Heimb\u00fcrger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55(5). https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00422.x.","DOI":"10.1046\/j.1523-1755.1999.00422.x"},{"key":"5407_CR12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2003.01175.x","author":"R Pecoits-Filho","year":"2003","unstructured":"Pecoits-Filho R, Lindholm B, Stenvinkel P. End-stage renal disease: a state of chronic inflammation and hyperleptinemia. Clin Sci (Lond). 2003. https:\/\/doi.org\/10.1046\/j.1365-2362.2003.01175.x.","journal-title":"Clin Sci (Lond)"},{"key":"5407_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3494867","author":"V Liakopoulos","year":"2017","unstructured":"Liakopoulos V, Roumeliotis S, Gorny X, Eleftheriadis T, Mertens PR. Oxidative stress in patients undergoing peritoneal dialysis: a current review of the literature. Oxid Med Cell Longev. 2017. https:\/\/doi.org\/10.1155\/2017\/3494867.","journal-title":"Oxid Med Cell Longev"},{"issue":"12","key":"5407_CR14","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3390\/cells12121581","volume":"12","author":"SP Kadatane","year":"2023","unstructured":"Kadatane SP, Satariano M, Massey M, Mongan K, Raina R. The role of inflammation in CKD. Cells. 2023;12(12):1581. https:\/\/doi.org\/10.3390\/cells12121581.","journal-title":"Cells"},{"key":"5407_CR15","doi-asserted-by":"publisher","first-page":"2180373","DOI":"10.1155\/2018\/2180373","volume":"2018","author":"S Mihai","year":"2018","unstructured":"Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res. 2018;2018:2180373. https:\/\/doi.org\/10.1155\/2018\/2180373.","journal-title":"J Immunol Res"},{"issue":"4","key":"5407_CR16","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1096\/FJ.11-201442","volume":"26","author":"CN Serhan","year":"2012","unstructured":"Serhan CN, Dalli J, Colby JK, Winkler JW, Chiang N, Petasis NA. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 2012;26(4):1755. https:\/\/doi.org\/10.1096\/FJ.11-201442.","journal-title":"FASEB J"},{"key":"5407_CR17","doi-asserted-by":"publisher","unstructured":"Dalli J, Chiang N, Serhan CN. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J. 2013;27(7). https:\/\/doi.org\/10.1096\/fj.13-227728.","DOI":"10.1096\/fj.13-227728"},{"issue":"19","key":"5407_CR18","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1021\/acs.biochem.0c00233","volume":"59","author":"C Freedman","year":"2020","unstructured":"Freedman C, et al. Biosynthesis of the Maresin intermediate, 13S,14S-epoxy-DHA, by human 15-lipoxygenase and 12-lipoxygenase and its regulation through negative allosteric modulators. Biochemistry. 2020;59(19):1832\u201344. https:\/\/doi.org\/10.1021\/acs.biochem.0c00233.","journal-title":"Biochemistry"},{"key":"5407_CR19","doi-asserted-by":"publisher","unstructured":"Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med. 2009;206(1). https:\/\/doi.org\/10.1084\/jem.20081880.","DOI":"10.1084\/jem.20081880"},{"key":"5407_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114147","author":"S Bindu","year":"2020","unstructured":"Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020. https:\/\/doi.org\/10.1016\/j.bcp.2020.114147.","journal-title":"Biochem Pharmacol"},{"key":"5407_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fimmu.2013.00013","volume":"4","author":"S Hong","year":"2013","unstructured":"Hong S, Lu Y. Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: targeting novel lipid mediator pathways in mitigation of acute kidney injury. Front Immunol. 2013;4:13. https:\/\/doi.org\/10.3389\/fimmu.2013.00013.","journal-title":"Front Immunol"},{"key":"5407_CR22","doi-asserted-by":"publisher","first-page":"2438247","DOI":"10.1155\/2017\/2438247","volume":"2017","author":"S Tang","year":"2017","unstructured":"Tang S, et al. Maresin 1 mitigates high glucose-induced mouse glomerular mesangial cell injury by inhibiting inflammation and fibrosis. Mediators Inflamm. 2017;2017:2438247. https:\/\/doi.org\/10.1155\/2017\/2438247.","journal-title":"Mediators Inflamm"},{"key":"5407_CR23","doi-asserted-by":"publisher","unstructured":"Qiu Y, Wu Y, Zhao H, Sun H, Gao S. Maresin 1 mitigates renal ischemia\/reperfusion injury in mice via inhibition of the TLR4\/MAPK\/NF-\u03baB pathways and activation of the Nrf2 pathway. Drug Des Devel Ther. 2019;13. https:\/\/doi.org\/10.2147\/DDDT.S188654.","DOI":"10.2147\/DDDT.S188654"},{"key":"5407_CR24","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014010117","author":"HJ Anders","year":"2014","unstructured":"Anders HJ, Schaefer L. Beyond tissue injury\u2014damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J Am Soc Nephrol. 2014. https:\/\/doi.org\/10.1681\/ASN.2014010117.","journal-title":"J Am Soc Nephrol"},{"key":"5407_CR25","doi-asserted-by":"publisher","first-page":"111784","DOI":"10.1016\/J.CBI.2025.111784","volume":"421","author":"H Liu","year":"2025","unstructured":"Liu H, et al. Oxidative stress and inflammation in renal fibrosis: novel molecular mechanisms and therapeutic targets. Chem Biol Interact. 2025;421:111784. https:\/\/doi.org\/10.1016\/J.CBI.2025.111784.","journal-title":"Chem Biol Interact"},{"key":"5407_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0248-y","author":"M Ruiz-Ortega","year":"2020","unstructured":"Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020. https:\/\/doi.org\/10.1038\/s41581-019-0248-y.","journal-title":"Nat Rev Nephrol"},{"key":"5407_CR27","doi-asserted-by":"publisher","first-page":"2180373","DOI":"10.1155\/2018\/2180373","volume":"2018","author":"S Mihai","year":"2018","unstructured":"Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res. 2018;2018:2180373. https:\/\/doi.org\/10.1155\/2018\/2180373.","journal-title":"J Immunol Res"},{"key":"5407_CR28","doi-asserted-by":"publisher","unstructured":"Ying T, Clayton P, Naresh C, Chadban S. Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression. BMC Nephrol. 2018;19(1). https:\/\/doi.org\/10.1186\/S12882-018-0853-1.","DOI":"10.1186\/S12882-018-0853-1"},{"key":"5407_CR29","doi-asserted-by":"publisher","unstructured":"Paisley KE, Beaman M, Tooke JE, Mohamed-Ali V, Lowe GDO, Shore AC. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int. 2003;63(2). https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00768.x.","DOI":"10.1046\/j.1523-1755.2003.00768.x"},{"key":"5407_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/J.MAM.2017.05.001","volume":"58","author":"EP Brennan","year":"2017","unstructured":"Brennan EP, Cacace A, Godson C. Specialized pro-resolving mediators in renal fibrosis. Mol Aspects Med. 2017;58:102\u201313. https:\/\/doi.org\/10.1016\/J.MAM.2017.05.001.","journal-title":"Mol Aspects Med"},{"key":"5407_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13119","author":"J Tecklenborg","year":"2018","unstructured":"Tecklenborg J, Clayton D, Siebert S, Coley SM. The role of the immune system in kidney disease. Clin Exp Immunol. 2018. https:\/\/doi.org\/10.1111\/cei.13119.","journal-title":"Clin Exp Immunol"},{"key":"5407_CR32","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005070757","author":"M Nangaku","year":"2006","unstructured":"Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006. https:\/\/doi.org\/10.1681\/ASN.2005070757.","journal-title":"J Am Soc Nephrol"},{"key":"5407_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2014.114","author":"XM Meng","year":"2014","unstructured":"Meng XM, Nikolic-Paterson DJ, Lan HY. Inflammatory processes in renal fibrosis. Nat Rev Nephrol. 2014. https:\/\/doi.org\/10.1038\/nrneph.2014.114.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"5407_CR34","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1046\/J.1523-1755.1999.00744.X","volume":"56","author":"R Sayers","year":"1999","unstructured":"Sayers R, Kalluri R, Rodgers KD, Shield CF, Meehan DT, Cosgrove D. Role for transforming growth factor-\u03b21 in Alport renal disease progression. Kidney Int. 1999;56(5):1662\u201373. https:\/\/doi.org\/10.1046\/J.1523-1755.1999.00744.X.","journal-title":"Kidney Int"},{"key":"5407_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.418","author":"SB Lee","year":"2010","unstructured":"Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int. 2010. https:\/\/doi.org\/10.1038\/ki.2010.418.","journal-title":"Kidney Int"},{"key":"5407_CR36","doi-asserted-by":"publisher","unstructured":"Tang PMK, Zhang YY, Mak TSK, Tang PCT, Huang XR, Lan HY. Transforming growth factor-\u03b2 signalling in renal fibrosis: from Smads to non-coding RNAs. J Physiol. 2018;596(16). https:\/\/doi.org\/10.1113\/JP274492.","DOI":"10.1113\/JP274492"},{"key":"5407_CR37","doi-asserted-by":"publisher","first-page":"7177889","DOI":"10.1155\/2022\/7177889","volume":"2022","author":"X Li","year":"2022","unstructured":"Li X, et al. Maresin 1 alleviates diabetic kidney disease via LGR6-mediated cAMP-SOD2-ROS pathway. Oxid Med Cell Longev. 2022;2022:7177889. https:\/\/doi.org\/10.1155\/2022\/7177889.","journal-title":"Oxid Med Cell Longev"},{"key":"5407_CR38","doi-asserted-by":"publisher","first-page":"782660","DOI":"10.3389\/FPHAR.2021.782660","volume":"12","author":"J Li","year":"2021","unstructured":"Li J, et al. Maresin 1 attenuates lipopolysaccharide-induced acute kidney injury via inhibiting NOX4\/ROS\/NF-\u03baB pathway. Front Pharmacol. 2021;12:782660. https:\/\/doi.org\/10.3389\/FPHAR.2021.782660.","journal-title":"Front Pharmacol"},{"key":"5407_CR39","doi-asserted-by":"publisher","unstructured":"Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes. 2010;59(4). https:\/\/doi.org\/10.2337\/db09-1342.","DOI":"10.2337\/db09-1342"},{"key":"5407_CR40","doi-asserted-by":"publisher","DOI":"10.1042\/CS20150436","author":"O Al-Sawaf","year":"2015","unstructured":"Al-Sawaf O, et al. Nrf2 in health and disease: current and future clinical implications. Clin Sci (Lond). 2015. https:\/\/doi.org\/10.1042\/CS20150436.","journal-title":"Clin Sci (Lond)"},{"key":"5407_CR41","doi-asserted-by":"publisher","first-page":"101266","DOI":"10.1016\/j.redox.2019.101266","volume":"26","author":"MC Lu","year":"2019","unstructured":"Lu MC, et al. CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-\u03baB activation. Redox Biol. 2019;26:101266. https:\/\/doi.org\/10.1016\/j.redox.2019.101266.","journal-title":"Redox Biol"},{"issue":"9","key":"5407_CR42","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/J.BBADIS.2019.05.010","volume":"1865","author":"YL Feng","year":"2019","unstructured":"Feng YL, et al. Activated NF-\u03baB\/Nrf2 and Wnt\/\u03b2-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2317\u201332. https:\/\/doi.org\/10.1016\/J.BBADIS.2019.05.010.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"5407_CR43","doi-asserted-by":"publisher","unstructured":"Lu Y, et al. Activation of NRF2 ameliorates oxidative stress and cystogenesis in autosomal dominant polycystic kidney disease. Sci Transl Med. 2020;12(554). https:\/\/doi.org\/10.1126\/SCITRANSLMED.ABA3613.","DOI":"10.1126\/SCITRANSLMED.ABA3613"},{"key":"5407_CR44","doi-asserted-by":"publisher","unstructured":"Juul-Nielsen C, Shen J, Stenvinkel P, Scholze A. Systematic review of the nuclear factor erythroid 2-related factor 2 (NRF2) system in human chronic kidney disease: alterations, interventions and relation to morbidity. Nephrol Dial Transpl. 2022;37(5). https:\/\/doi.org\/10.1093\/ndt\/gfab031.","DOI":"10.1093\/ndt\/gfab031"},{"issue":"12","key":"5407_CR45","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/S11255-015-1135-5","volume":"47","author":"VO Leal","year":"2015","unstructured":"Leal VO, et al. NRF2 and NF-\u03baB mRNA expression in chronic kidney disease: a focus on nondialysis patients. Int Urol Nephrol. 2015;47(12):1985\u201391. https:\/\/doi.org\/10.1007\/S11255-015-1135-5.","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"5407_CR46","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3109\/00498254.2013.852705","volume":"44","author":"MA Aminzadeh","year":"2014","unstructured":"Aminzadeh MA, Reisman SA, Vaziri ND, Khazaeli M, Yuan J, Meyer CJ. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica. 2014;44(6):570\u20138. https:\/\/doi.org\/10.3109\/00498254.2013.852705.","journal-title":"Xenobiotica"},{"key":"5407_CR47","doi-asserted-by":"publisher","unstructured":"Tsai PY, et al. Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice. Free Radic Biol Med. 2011;50(11). https:\/\/doi.org\/10.1016\/j.freeradbiomed.2011.02.029.","DOI":"10.1016\/j.freeradbiomed.2011.02.029"},{"key":"5407_CR48","doi-asserted-by":"publisher","unstructured":"Tosi MER, Bocanegra V, Manucha W, Lorenzo AG, Vall\u00e9s PG. The Nrf2-Keap1 cellular defense pathway and heat shock protein 70 (Hsp70) response: role in protection against oxidative stress in early neonatal unilateral ureteral obstruction (UUO). Cell Stress Chaperones. 2011;16(1). https:\/\/doi.org\/10.1007\/s12192-010-0221-y.","DOI":"10.1007\/s12192-010-0221-y"},{"key":"5407_CR49","doi-asserted-by":"publisher","first-page":"119467","DOI":"10.1016\/j.lfs.2021.119467","volume":"277","author":"D Li","year":"2021","unstructured":"Li D, et al. Maresin 1 alleviates the inflammatory response, reduces oxidative stress and protects against cardiac injury in LPS-induced mice. Life Sci. 2021;277:119467. https:\/\/doi.org\/10.1016\/j.lfs.2021.119467.","journal-title":"Life Sci"},{"key":"5407_CR50","doi-asserted-by":"publisher","unstructured":"Soto G, et al. Maresin 1, a proresolving lipid mediator, ameliorates liver ischemia-reperfusion injury and stimulates hepatocyte proliferation in Sprague-Dawley rats. Int J Mol Sci. 2020;21(2). https:\/\/doi.org\/10.3390\/ijms21020540.","DOI":"10.3390\/ijms21020540"},{"key":"5407_CR51","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez MJ, et al. Pro-resolving lipid mediator resolvin E1 mitigates the progress of diethylnitrosamine-induced liver fibrosis in Sprague-Dawley rats by attenuating fibrogenesis and restricting proliferation. Int J Mol Sci. 2020;21(22). https:\/\/doi.org\/10.3390\/ijms21228827.","DOI":"10.3390\/ijms21228827"},{"key":"5407_CR52","doi-asserted-by":"publisher","unstructured":"AlZahrani S, Shinwari Z, Gaafar A, Alaiya A, Al-Kahtani A. Anti-inflammatory effect of specialized proresolving lipid mediators on mesenchymal stem cells: an in vitro study. Cells. 2023;12(1). https:\/\/doi.org\/10.3390\/cells12010122.","DOI":"10.3390\/cells12010122"},{"key":"5407_CR53","doi-asserted-by":"publisher","unstructured":"Wang Y, et al. Maresin 1 inhibits epithelial-to-mesenchymal transition in vitro and attenuates bleomycin-induced lung fibrosis in vivo. Shock. 2015;44(5). https:\/\/doi.org\/10.1097\/SHK.0000000000000446.","DOI":"10.1097\/SHK.0000000000000446"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05407-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05407-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05407-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:17:24Z","timestamp":1791933444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05407-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5407"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05407-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8333931\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This prospective, controlled, cross-sectional study was conducted in accordance with the Declaration of Helsinki and approved by the Local Ethics Committee of Atat\u00fcrk University Faculty of Medicine (Approval No: B.30.2.ATA.0.01.00\/639). Written informed consent to participate was obtained from the parents or legal guardians of all patients.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"608"}}